Earnings History Data for 4D Molecular Therapeutics (FDMT) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
4D Molecular Therapeutics
4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology and pulmonology therapeutic areas. 4D Molecular Therapeutics Inc. is based in Emeryville, California.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29-02-2024 | AH | FDMT | 4D Molecular Therapeutics | 1,279 | -0.77 | -0.68 | 0.00 | 4D Molecular Therapeutics GAAP EPS of -$2.58 [2/29/2024 6:06 PM] |
29.42 | 1.40 (5.00%) |
28.80 | 0.78 (2.78%) |
9.44 - 35.61 | 515,609 | 730,000 | 408 | ||
| 09-11-2023 | AH | FDMT | 4D Molecular Therapeutics | 500.00 | -0.24 | -0.67 | 0.00 | 4D Molecular Therapeutics GAAP EPS of -$0.24 beats by $0.37, revenue of $20.2M beats by $10.98M [11/9/2023 5:50 PM] |
11.04 | 0.54 (5.14%) |
10.75 | 0.25 (2.38%) |
8.57 - 26.49 | 331,856 | 320,000 | 1,623 | ||
| 09-08-2023 | AH | FDMT | 4D Molecular Therapeutics | 544.00 | -0.77 | -0.77 | 0.00 | 4D Molecular Therapeutics GAAP EPS of -$0.77 misses by $0.01, revenue of $0.24M misses by $0.78M [8/9/2023 6:01 PM] |
16.55 | -0.48 (-2.85%) |
17.05 | 0.01 (0.06%) |
6.58 - 26.49 | 193,239 | 270,000 | 25,093 | ||
| 10-05-2023 | AH | 4:05 PM ET (May 10) |
FDMT | 4D Molecular Therapeutics | 532.00 | -0.88 | -0.88 | 0.00 | 4D Molecular Therapeutics GAAP EPS of -$0.88, revenue of $0.3M [5/10/2023 5:27 PM] |
16.81 | -0.84 (-4.76%) |
17.65 | 0.0 (0.00%) |
5.32 - 26.49 | 540,802 | 980,000 | 327,753 | |
| 15-03-2023 | AH | 4:05 PM ET (Mar 15) |
FDMT | 4D Molecular Therapeutics | 567.00 | -0.84 | -0.75 | 0.00 | 4D Molecular Therapeutics GAAP EPS of -$3.32 misses by $0.12, revenue of $3.13M misses by $1.28M [3/15/2023 4:51 PM] |
18.41 | 1.04 (6.02%) |
0.0 | 0.0 (0.00%) |
5.32 - 26.49 | 420,382 | 400,000 | 0 | |
| 28-03-2022 | AH | FDMT | 4D Molecular Therapeutics | 531.00 | -0.85 | -0.82 | 0.00 | 4D Molecular Therapeutics GAAP EPS of -$2.57, revenue of $18.03M [3/28/2022 4:38 PM] |
16.19 | 0.78 (5.06%) |
15.41 | 0.0 (0.00%) |
12.84 - 44.03 | 183,869 | 160,000 | 731 | ||
| 10-11-2021 | AH | FDMT | 4D Molecular Therapeutics | 673.00 | -0.82 | -0.83 | 0.00 | 4D Molecular Therapeutics EPS beats by $0.01 [11/10/2021 4:41 PM] |
24.78 | 0.06 (0.23%) |
24.72 | 0.0 (0.00%) |
21.40 - 55.11 | 162,661 | 500,000 | 1,301 | ||